Table 2

Baseline characteristics and 5-year survival predicted and observed in the patients with surgery plus chemotherapy
Mean % of 5-Year outcomes % Delta (Pred-Obs)
Number % AOL predicted YTR observed (95% CI)
All patients 765 100 78.19 79.35 (76.3, 82.05) −1.16
Age
 < 50 177 23.1 83.37 87.57 (81.74, 91.63) −4.2
 50-59 226 29.5 79.56 80.09 (74.26, 84.73) −0.53
 60-69 270 35.3 76.51 76.3 (70.76, 80.93) 0.21
 ≥ 70 92 12.1 69.75 70.65 (60.2, 78.84) −0.9
Sex
 Male 450 58.8 77.57 78.67 (74.59, 82.17) −1.1
 Female 315 41.2 79.06 80.32 (75.48, 84.3) −1.26
T stage
 T1 4 0.5 89.50 75 (12.79, 96.05) 14.5
 T2 20 2.6 82.35 85 (60.38, 94.9) −2.65
 T3 712 93.1 78.78 80.48 (77.37, 83.2) −1.7
 T4 29 3.8 59.21 48.28 (29.47, 64.78) 10.93
Number of positive node
 0 420 54.9 86.87 86.43 (82.77, 89.36) 0.44
 1-3 242 31.6 74.31 77.27 (71.46, 82.05) −2.96
 4-10 79 10.3 57.24* 69.62 (58.19, 78.49) −12.38
 > 10 24 3.2 34.25* 8.33 (1.44, 23.3) 25.92
Number of examined nodes
 1-3 3 0.4 79.33* 100 (100, 100) −20.67
 4-10 83 10.9 76.77 77.11 (66.49, 84.74) −0.34
 > 10 679 88.7 78.35 79.53 (76.29, 82.37) −1.18
Histologic grade
 1 94 12.3 82.44 81.91 (72.53, 88.35) 0.53
 2 561 73.3 78.52 79.14 (75.54, 82.28) −0.62
 3 44 5.8 69.50 72.73 (57, 83.49) −3.23
 Undefined 66 8.6 75.09 81.82 (70.21, 89.24) −6.73

*This predicted estimate is outside the 95% CI of the Kaplan-Meier estimate.

AOL: Adjuvant Online; YTR: Yonsei Tumor registry; CI: confidential interval; Pred: predicted; Obs: observed.

Jung et al.

Jung et al. BMC Cancer 2012 12:471   doi:10.1186/1471-2407-12-471

Open Data